Father’s Day Sale: 15% off Sitewide w/code DAD15 (excludes sale items / ends Sun 6/21 at 9pm CST)
ANNIV40 for 40% OFF sitewide (no stacking, no sale items) ANNIV40 for 40% OFF sitewide (no stacking, no sale items) ANNIV40 for 40% OFF sitewide (no stacking, no sale items) ANNIV40 for 40% OFF sitewide (no stacking, no sale items) ANNIV40 for 40% OFF sitewide (no stacking, no sale items)

What Is DSIP Peptide? Delta Sleep-Inducing Peptide in the Published Research

DSIP peptide (delta sleep-inducing peptide) is a nine-amino-acid peptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, isolated in 1977 from the blood of rabbits by a group in Basel. It is named for the slow-wave “delta” brain activity it raised in those rabbits. A 2006 review found that no DSIP gene, protein or receptor had been isolated.

So the chemistry of DSIP is exact and its biology is still open, which leaves identity and purity as the parts a researcher can check. Below, Renovita Research sets out what the 1977 papers established, what the human studies found (including the controlled trials that found little), and how to read the lot certificate for Renovita Research’s DSIP-15mg (RESEARCH USE ONLY).

Key takeaways

  • DSIP is an exact chemical sequence with a molecular weight of 849, first characterized in 1977 (Schoenenberger and Monnier, PNAS 1977; Graf and Kastin, 1984).
  • In the 1978 sequence paper, only the alpha-aspartyl form was highly active; its beta-aspartyl isomer was not (Schoenenberger et al., 1978).
  • Studies led by Schneider-Helmert in insomniacs reported better sleep. Two double-blind trials by other authors judged the effect weak or of little clinical significance (Monti et al., 1987; Bes et al., 1992).
  • A 2006 review called the link between DSIP and sleep “extremely poorly documented and still weak” (Kovalzon and Strekalova, 2006).
  • The certificate for Renovita’s DSIP lot MYA2605DS15 reports 99.9% HPLC purity, identity confirmed by FTIR, and peptide content within its 90% to 110% specification (lot certificate).

What is DSIP?

DSIP is a nonapeptide: a chain of nine amino acids in the order tryptophan, alanine, glycine, glycine, aspartic acid, alanine, serine, glycine, glutamic acid. The sequence was published in 1977 by Schoenenberger and Monnier (PNAS 1977), and a 1984 review gives its molecular weight as 849 (Graf and Kastin, 1984).

Three facts define it for a laboratory:

  1. Sequence: Trp–Ala–Gly–Gly–Asp–Ala–Ser–Gly–Glu.
  2. Size: nine residues, MW 849.
  3. Form that matters: the alpha-aspartyl peptide. The 1978 paper found that only this form was highly active, in contrast to its beta-Asp isomer (Schoenenberger et al., 1978).

Two molecules with the same nine amino acids can differ in how the aspartic acid is linked, and in the original tests that difference separated a highly active peptide from one that was not. The structure itself stands apart: a 2006 review in the Journal of Neurochemistry found it different from any other known peptide family (Kovalzon and Strekalova, 2006).

How delta sleep-inducing peptide was discovered in 1977

Delta sleep-inducing peptide was found by electrically stimulating a sleep-linked area of the thalamus in rabbits, collecting the blood leaving their brains, and testing what was in it. The Basel group isolated the peptide from that cerebral venous blood, sequenced it, and then made it synthetically (Schoenenberger et al., 1978).

The test that gave DSIP its name was tightly built:

  • Nine synthetic peptides were compared: DSIP, five possible breakdown fragments, two altered versions and a related tripeptide.
  • 61 rabbits, including controls, received them into the brain under double-blind conditions.
  • Brain recordings from the neocortex and the limbic cortex were analyzed by computer.

Only synthetic DSIP raised delta and spindle activity. Delta activity rose by a mean of 35% against controls, and none of the other eight peptides matched it (Schoenenberger et al., 1978). The 1977 PNAS report of the same work counted 58 rabbits (PNAS 1977). The same group also compared the natural and synthetic forms in a separate 1977 paper (Monnier et al., 1977).

Does DSIP cross the blood-brain barrier?

Studies in rabbits, rats and dogs reported that some DSIP passes from the blood into the brain or the fluid around it. That mattered, because the 1977 work had delivered the peptide straight into the brain.

YearSpeciesWhat was measuredReported findingSource
1977RabbitBrain activity and movement after injection into a veinDelta activity rose and movement fell for 5 hoursMonnier et al., 1977
1979RatBrain levels by immunoassay after injection into the carotid arteryBrain levels of essentially intact peptide doubledKastin et al., 1979
1986DogDSIP and four analogs in spinal fluid after injection into a veinEntry tracked plasma level, plasma half-life and fat solubility, not molecular weightBanks et al., 1986

In the 1979 rat study, the antibody needed eight of the nine amino acids to recognize the peptide, so what it measured in the brain was close to the whole molecule, not fragments (Kastin et al., 1979).

What did the human studies of DSIP find?

The human studies of DSIP were small, and their results track who ran them. Studies led by Schneider-Helmert from 1981 to 1987, the first two co-authored with Schoenenberger, who isolated DSIP, reported better sleep in insomniacs. Double-blind trials by two other author groups, in 1987 and 1992, found the effect small. By 1997, a review in Sleep listed DSIP’s role in human sleep regulation as “not yet clear” (Steiger and Holsboer, 1997).

YearDesignWho was studiedReported findingSource
1981Double-blind crossover6 healthy volunteersTotal sleep time up 59% (median) in the 130 minutes after it was given, against placebo; no sedation in the classic pharmacologic waySchneider-Helmert et al., 1981
1981Acute study6 middle-aged chronic insomniacsLonger, less interrupted sleep; a slight arousing effect in the first hourSchneider-Helmert and Schoenenberger, 1981
1984Open study7 patients with severe insomniaSleep normalized in all but 1 for 3 to 7 months of follow-upKaeser, 1984
1986Sleep laboratory study18 chronic insomniacs, aged 29 to 83Sleep reached normal values by the end of follow-up; effect tracked how disturbed sleep wasSchneider-Helmert, 1986
1987Placebo-controlled, double-blind14 middle-aged chronic insomniacsNight sleep and daytime alertness improvedSchneider-Helmert, 1987
1987Double-blind crossoverChronic insomniacsSome measures moved, but the authors concluded the improvement was “of little clinical significance”Monti et al., 1987
1992Double-blind matched pairs16 chronic insomniacsHigher sleep efficiency and shorter sleep latency, but effects were weak and partly explained by a change in the placebo groupBes et al., 1992

Every strongly positive result in that table came from Schneider-Helmert’s studies or an open study with no placebo arm; his 1987 trial was itself placebo-controlled and double-blind. The two double-blind trials by other authors both measured small changes and judged them unlikely to matter clinically.

The human record is also small. Every trial in the table that gives its size in the abstract studied 18 people or fewer. A 1998 open trial looked at DSIP during opioid withdrawal, and a 2009 study tested it alongside anaesthesia (Backmund et al., 1998; Pomfrett et al., 2009). None of these established a use. They are the published record a researcher works from today.

DSIP and stress hormones: the results conflict

DSIP was studied as a brake on ACTH, the pituitary hormone that drives cortisol release. The human studies that found lower ACTH measured it at rest; the one that found no change measured it after stimulation.

  • Lower ACTH at rest: in 11 healthy men, plasma ACTH-like activity fell for at least 3 hours after DSIP against saline, while cortisol followed its normal daily decline (Bjartell et al., 1989). A 1994 study in 8 men also reported a significant fall in ACTH, with no change in vasopressin (Chiodera et al., 1994).
  • No change after stimulation: a 1995 study found ACTH and cortisol responses almost identical under DSIP and placebo, both after a stimulating hormone and after a midday meal, and concluded the data “do not support an inhibitory role” in humans (Späth-Schwalbe et al., 1995).
  • Growth hormone and prolactin: no effect in 8 healthy women (Giusti et al., 1993).

Why is DSIP still called a riddle?

DSIP is called a riddle because the molecule is known and the biology behind it is not. The 2006 review that gave it that label, “a still unresolved riddle”, set out the problems (Kovalzon and Strekalova, 2006):

  1. No DSIP gene, protein or receptor had been isolated, so its natural source and target were unknown.
  2. DSIP-like immunoreactivity is found in neurosecretory nuclei of the hypothalamus that are not closely tied to sleep.
  3. In the review authors’ own rabbit and rat studies, certain artificial analogs of DSIP promoted slow-wave sleep, but DSIP itself did not.
  4. A natural decapeptide that shares five of DSIP’s nine positions did promote slow-wave sleep in rabbits.

The authors proposed that a related, still unidentified “DSIP-like” peptide may explain some of the activity credited to DSIP.

Other papers add to the puzzle. A 1984 review reported a U-shaped activity curve for both the dose and the time of infusion in animal work, and a separate 1984 study reported indications of bell-shaped dose-response curves in most of its tests (Graf and Kastin, 1984; Scherschlicht et al., 1984). In cats, the main effect was on REM sleep rather than delta sleep (same review; Scherschlicht et al., 1984). And in the 2009 anaesthesia study, DSIP reduced delta rhythm, the opposite of what its name predicts; the authors called the result paradoxical (Pomfrett et al., 2009).

In serum, a labeled DSIP (125I-Tyr-DSIP) separated into four peaks, one bound to protein and one tied to iron, which the authors read as consistent with peptides occurring in multiple forms (Kastin et al., 1984).

What recent DSIP research has studied

The four DSIP papers below, from 2017 to 2024, are animal and engineering studies in rodent models.

YearModelWhat was studiedReported findingSource
2017MiceDSIP fused to a carrier protein, made in yeastShorter sleep latency and longer sleep in a pentobarbital sleep testZhang et al., 2017
2021Rats, focal strokeDSIP given through the nose for 8 daysFaster recovery of motor function; smaller infarct size was not statistically significantTukhovskaya et al., 2021
2021Rats and mice, heart attack and strokeKND, a structural analog of DSIPSmaller infarcts when given during reperfusion; a pilot giving DSIP during occlusion in the heart model ended in 100% mortalityTukhovskaya et al., 2021
2024Mice, induced insomnia modelDSIP fused to a blood-brain-barrier carrier peptideThe fusion corrected neurotransmitter changes better than DSIP aloneMu et al., 2024

Three of the four build on the DSIP sequence, as a fusion protein or an analog, rather than testing the plain peptide.

How to read the certificate for Renovita’s DSIP lot

A DSIP certificate is where the exact chemistry meets the vial. Renovita Research links the certificate for its DSIP lot from the DSIP-15mg (RESEARCH USE ONLY) product page. It was issued by an independent third-party lab. Here is what it reports (lot certificate, PDF):

Line on the certificateSpecificationResultWhat it tells a researcher
Lot numberMYA2605DS15The batch this report covers
Date tested / report dateMay 6, 2026 / May 11, 2026How recent the analysis is
AppearanceWhite powderWhite powderVisual check of the powder in the vial
HPLC purity98% or higher99.9%Share of the HPLC signal in the main peak
HPLC traceRead at 280 nm, one peak listed (retention 1.951 min)The chromatogram behind the purity figure
HPLC potency90% to 110% of 15 mgWithin specificationMeasured peptide against the 15 mg label
FTIR identificationSpectrum confirms the peptideConfirms DSIP, with excipientsIdentity check by infrared spectrum
Peptide to excipient ratio1:2 to 1:10 recommended1:3.7How much of the vial’s powder is filler

“Excipient” is the inactive powder that bulks out a small amount of peptide; in this lot, each part of DSIP sits with about 3.7 parts of excipient, inside the range the certificate prints. The certificate also states its own limits: it does not cover particulate matter, microbial contamination or endotoxins, and no line on it names the aspartyl form.

DSIP is also sold as DSIP-10mg (RESEARCH USE ONLY). Both are research-grade peptides sold strictly for laboratory and research use only, not for human or animal consumption, and Renovita Research ships only to addresses within the United States.

DSIP questions researchers ask

Is DSIP a hormone?

The papers leave that unsettled. As of 2006, no DSIP gene, protein or receptor had been isolated, and its natural occurrence remained obscure (Kovalzon and Strekalova, 2006). DSIP-like material has been measured in the brain and peripheral organs of the rat and in the plasma of several mammals (Graf and Kastin, 1984).

Is DSIP the same as KND?

DSIP and KND are different peptides. KND is a structural analog of DSIP, studied by a Russian Academy of Sciences group in rat and mouse models of heart attack and stroke (Tukhovskaya et al., 2021).

Why do the DSIP sleep studies disagree?

The DSIP sleep studies disagree by design and by author. The strongly positive human results came from Schneider-Helmert’s studies and an open study, while two double-blind trials by other authors judged the effect weak (Monti et al., 1987; Bes et al., 1992). Animal work adds a U-shaped activity curve and species differences (Graf and Kastin, 1984).

What should a DSIP certificate show?

A DSIP certificate should show the lot number, an identity test, HPLC purity against a stated specification, and measured content against the label. The certificate for Renovita’s lot MYA2605DS15 reports all four: FTIR identity, 99.9% purity against a 98% specification, and peptide content within 90% to 110% of the 15 mg label (lot certificate).

Papers cited

  • Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proc Natl Acad Sci USA. 1977. PMC430668
  • Monnier M et al. The delta sleep inducing peptide (DSIP). Comparative properties of the original and synthetic nonapeptide. Experientia. 1977. PMID 862769
  • Monnier M et al. Transport of the synthetic peptide DSIP through the blood-brain barrier in rabbit. Experientia. 1977. PMID 590449
  • Schoenenberger GA et al. The delta EEG (sleep)-inducing peptide (DSIP). XI. Amino-acid analysis, sequence, synthesis and activity of the nonapeptide. Pflugers Arch. 1978. PMID 568769
  • Kastin AJ et al. Additional evidence that small amounts of a peptide can cross the blood-brain barrier. Pharmacol Biochem Behav. 1979. PMID 583452
  • Schneider-Helmert D et al. Acute and delayed effects of DSIP on human sleep behavior. Int J Clin Pharmacol Ther Toxicol. 1981. PMID 6895513
  • Schneider-Helmert D, Schoenenberger GA. The influence of synthetic DSIP on disturbed human sleep. Experientia. 1981. PMID 7028502
  • Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): a review. Neurosci Biobehav Rev. 1984. PMID 6145137
  • Kaeser HE. A clinical trial with DSIP. Eur Neurol. 1984. PMID 6391926
  • Scherschlicht R et al. Some pharmacological effects of delta-sleep-inducing peptide (DSIP). Eur Neurol. 1984. PMID 6548967
  • Kastin AJ et al. Evidence for peptide aggregation. Pharmacol Biochem Behav. 1984. PMID 6151671
  • Banks WA et al. Entry of DSIP peptides into dog CSF. Brain Res Bull. 1986. PMID 3768731
  • Schneider-Helmert D. Efficacy of DSIP to normalize sleep in middle-aged and elderly chronic insomniacs. Eur Neurol. 1986. PMID 3792404
  • Schneider-Helmert D. Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. Eur Neurol. 1987. PMID 3622582
  • Monti JM et al. Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. Int J Clin Pharmacol Res. 1987. PMID 3583493
  • Bjartell A et al. Reduction of immunoreactive ACTH in plasma following intravenous injection of delta sleep-inducing peptide in man. Psychoneuroendocrinology. 1989. PMID 2554357
  • Bes F et al. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology. 1992. PMID 1299794
  • Giusti M et al. Delta sleep-inducing peptide administration does not influence growth hormone and prolactin secretion in normal women. Psychoneuroendocrinology. 1993. PMID 8475226
  • Chiodera P et al. Different effects of delta-sleep-inducing peptide on arginine-vasopressin and ACTH secretion in normal men. Horm Res. 1994. PMID 7698722
  • Späth-Schwalbe E et al. Delta-sleep-inducing peptide does not affect CRH and meal-induced ACTH and cortisol secretion. Psychoneuroendocrinology. 1995. PMID 7777652
  • Steiger A, Holsboer F. Neuropeptides and human sleep. Sleep. 1997. PMID 9456470
  • Backmund M et al. Opioid detoxification with delta sleep-inducing peptide: results of an open clinical trial. J Clin Psychopharmacol. 1998. PMID 9617990
  • Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem. 2006. PMID 16539679
  • Pomfrett CJ et al. Delta sleep-inducing peptide alters bispectral index, the electroencephalogram and heart rate variability when used as an adjunct to isoflurane anaesthesia. Eur J Anaesthesiol. 2009. PMID 19142086
  • Zhang XG et al. Expression and purification of delta sleep-inducing peptide fused with protein transduction domain and human serum albumin in Pichia pastoris. Protein Pept Lett. 2017. PMID 28462721
  • Tukhovskaya EA et al. Delta sleep-inducing peptide recovers motor function in SD rats after focal stroke. Molecules. 2021. PMC8434407
  • Tukhovskaya EA et al. DSIP-like KND peptide reduces brain infarction in C57Bl/6 and reduces myocardial infarction in SD rats when administered during reperfusion. Biomedicines. 2021. PMC8069497
  • Mu X et al. Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models. Front Pharmacol. 2024. PMC11498945
Shopping Cart

Before You Enter

Renovita Research products are sold strictly for laboratory and research use only. Please confirm the following before continuing.

Scroll to Top